Filing Flows › Cardiff Oncology (CRDF) › Who owns the stock
Who owns Cardiff Oncology (CRDF) stock
94 funds reported Cardiff Oncology (CRDF) shares in their latest 13F filings, worth $34.5M in all. The largest holder is Vanguard Group ($10.5M). Last quarter 47 funds added to their stakes and 50 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Vanguard Group | 3,722,085 | $10.5M | increase | 2025-12-31 |
| Vanguard Capital Management LLC | 2,895,592 | $3.8M | increase | 2026-06-30 |
| Laurion Capital Management LP | 3,098,299 | $3.7M | unchanged | 2026-09-30 |
| Pfizer | 2,411,575 | $3.0M | unchanged | 2026-06-30 |
| Franklin Resources | 1,205,803 | $1.6M | unchanged | 2026-06-30 |
| BlackRock | 972,873 | $1.3M | decrease | 2026-06-30 |
| Blair William | 912,513 | $1.2M | decrease | 2026-06-30 |
| Geode Capital Management, LLC | 820,062 | $1.1M | decrease | 2026-06-30 |
| GoalVest Advisory LLC | 687,285 | $832K | new | 2026-09-30 |
| UBS Group AG | 638,699 | $830K | increase | 2026-06-30 |
| Jane Street Group, LLC | 607,900 | $790K | increase | 2026-06-30 |
| Vanguard Fiduciary Trust | 410,602 | $534K | decrease | 2026-06-30 |
| AQR Capital Management LLC | 346,353 | $450K | increase | 2026-06-30 |
| State Street | 331,395 | $431K | decrease | 2026-06-30 |
| Morgan Stanley | 246,095 | $320K | increase | 2026-06-30 |
Cardiff Oncology's latest quarter
Cardiff Oncology, Q2 2026: revenue $104K (-14% year over year), net loss $9.2M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most CRDF stock?
By the latest 13F filings: Vanguard Group ($10.5M); Vanguard Capital Management LLC ($3.8M); Laurion Capital Management LP ($3.7M); Pfizer ($3.0M); Franklin Resources ($1.6M).
What is the short interest in CRDF?
12,118,893 shares were sold short at the 2026-10-15 settlement, 0.37% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.